Arca
Skip to content
Tools
Tools

Hemorrhagic cystitis

Drug research and approvals for hemorrhagic cystitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 22, 2026, 2 studies of hemorrhagic cystitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 1 approved and 2 open orphan designations naming it.

  • Recruiting worldwide: 2
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 1
  • EU medicines: 0

Recruiting now

Newest posted first, of 2 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Phase 3 5

Phase 2 5

Phase 1 or earlier 1

FDA orphan designations

Approved first, then open designations, newest first
Dec 30, 1988MesnexFor use as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.Degussa CorporationApproved
Sep 29, 2021Allogeneic multi-virus specific T lymphocytes targeting BK…Treatment for Virus-associated hemorrhagic cystitisAlloVir, Inc.Designated
Jul 6, 2012TacrolimusTreatment of hemorrhagic cystitisXraiy LLCDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.